Amy L. Delson

机构：University of California, San Francisco, Breast Center · ORCID：0000-0002-2837-3218

发表论文 56 篇 · 总被引 1249 次 · h-index 10

代表论文

• Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors (2025 · Nature Communications · 被引 15)
• Immune Subtyping Identifies Patients With Hormone Receptor–Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial (2025 · JCO Precision Oncology · 被引 5)
• 314P The impact of changes in tumor mutational landscape during neoadjuvant therapy on tumor-informed ctDNA testing in breast cancer patients (2024 · Annals of Oncology · 被引 1)
• Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk ERBB2 -Negative Breast Cancer (2026 · JAMA Oncology)
• Circulating tumor DNA concentration at diagnosis is a modifiable prognostic factor for distant metastatic recurrence in patients with high-risk breast cancer receiving neoadjuvant therapy (2026 · medRxiv)
• Abstract B019: Clinical and molecular correlates of circulating tumor DNA (ctDNA) dynamics in breast tumors resistant to neoadjuvant therapy (NAT) (2024 · Clinical Cancer Research)